

cis-3-Hexenyl isovalerate

CAS-No.:	35154-45-1 The scope of this Standard includes, but is not limited to the CAS number(s) indicated above; any other CAS number(s) used to identify this fragrance ingredient should be considered in scope as well.
Synonyms:	cis-3-Hexenyl isovalerate (Z)-Hex-3-enyl isovalerate Hex-3-en-1-yl 3-methylbutanoate Isovaleric acid, 3-hexenyl ester, (z)- (Z)-3-Hexen-1-yl isovalerate

History:	Publication date:	2023 (Amendment 51)	Previous Publications:	Not applicable

Implementation	For new creation*:	March 30, 2024
dates:	For existing creation*:	October 30, 2025
	*These dates apply to the supply of fragrance mixtu	res (formulas) only, not to the
	finished consumer products in the marketplace.	

RECOMMENDATION:	RESTRICTION

MAXIMUM ACCEPTABLE CONCENTRATIONS IN THE FINISHED PRODUCT (%):						
Category 1	0.077 %	Category 7A	0.88 %			
Category 2	0.023 %	Category 7B	0.88 %			
Category 3	0.46 %	Category 8	0.037 %			
Category 4	0.43 %	Category 9	0.84 %			
Category 5A	0.11 %	Category 10A	1.8 %			
Category 5B	0.11 %	Category 10B	3.0 %			
Category 5C	0.11 %	Category 11A	0.037 %			
Category 5D	0.037 %	Category 11B	0.037 %			
Category 6	0.25 %	Category 12	No restriction			



cis-3-Hexenyl isovalerate

FLAVOR REQUIREMENTS:

Due to the possible ingestion of small amounts of fragrance ingredients from their use in products in Categories 1 and 6, materials must not only comply with IFRA Standards but must also be recognized as safe as a flavoring ingredient as defined by the IOFI Code of Practice (www.iofi.org). For more details see chapter 1 of the Guidance for the use of IFRA Standards.

CONTRIBUTIONS FROM OTHER SOURCES:

SEE ANNEX ON CONTRIBUTIONS FROM **OTHER SOURCES**

INTRINSIC PROPERTY MANAGEMENT:

DRIVING

RISK

DERMAL SENSITIZATION AND SYSTEMIC TOXICITY

RIFM SUMMARIES:

Maximum acceptable concentrations are based on a comprehensive safety assessment, considering various endpoints. Depending on the outcome of the safety assessment, it might be one or more endpoint(s) that will drive the derivation of the concentration levels. If more than one endpoint is of relevance, the maximum acceptable concentrations for each product category are derived from comparing maximum permitted level per endpoint consideration (e.g. dermal sensitization and/or systemic toxicity). Such maximum acceptable concentrations correspond to the lowest level obtained per category.

Additional information is available in the RIFM safety assessment for cis-3-Hexenyl isovalerate, which can downloaded from the RIFM Fragrance Material Safety Assessment Center: http://fragrancematerialsafetyresource.elsevier.com/.

EXPERT PANEL FOR FRAGRANCE SAFETY RATIONALE / CONCLUSION:

The Expert Panel for Fragrance Safety reviewed all the available data for cis-3-Hexenyl isovalerate and recommends the concentrations for the 12 different product categories, which are the maximum acceptable concentrations of cis-3-Hexenyl isovalerate in the various product categories.

REFERENCES:

The IFRA Standard on cis-3-Hexenyl isovalerate is based on at least one of the following publications:

- The RIFM Safety Assessment on cis-3-Hexenyl isovalerate if available at the RIFM Fragrance Material Safety Assessment Center: http://fragrancematerialsafetyresource.elsevier.com
- · Api A.M., Belsito D., Bruze M., Cadby P., Calow P., Dagli M. L., Dekant W., Dent M., Ellis G., Fryer A. D., Fukayama M., Griem P., Hickey C., Kromidas L., Lalko J., Liebler D.C., Miyachi Y., Politano V.T., Renskers K., Ritacco G., Salvito D., Schultz T.W., Sipes I. G., Smith B., Vitale D., Wilcox D.K. (2015). Criteria for the Research Institute for Fragrance Materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. Suppl:S1-S19 Chem Toxicol. 2015 Aug;82 (http://fragrancematerialsafetyresource.elsevier.com/sites/default/files/Criteria Document Final.pdf).
- · Salvito D.T., Senna R. J., Federle T.W. (2002). A framework for prioritizing fragrance materials for aquatic risk assessment. Environ Toxicol Chem. 2002;21:1301-1308



cis-3-Hexenyl isovalerate

(https://www.ncbi.nlm.nih.gov/pubmed/12069318).

Additional information on the application of IFRA Standards is available in the Guidance for the use of IFRA Standards, publicly available at www.ifrafragrance.org.